Inhibikase Therapeutics (IKT) investor relations material

Executive summary

• Lead product candidate IKT-001 for pulmonary arterial hypertension (PAH) is in a pivotal global Phase 3 trial, with first patient enrolled and regulatory approvals in 16 countries as of April 2026, leveraging the EMA FAST-EU initiative.

• Orphan Drug Designation application for IKT-001 submitted to the FDA in April 2026.

• Upcoming presentations of preclinical and Phase 1 data for IKT-001 at the American Thoracic Society International Conference in May 2026.

• No revenue generated; focus remains on R&D and advancing clinical programs.

Financial highlights

• Net loss for Q1 2026 was $16.4 million, up from $13.7 million in Q1 2025.

• Research and development expenses were $10.8 million in Q1 2026, up from $10.5 million in Q1 2025, which included a $7.4 million non-cash charge.

• Selling, general and administrative expenses rose to $7.4 million in Q1 2026, mainly due to higher stock-based compensation.

• Other income increased 58.9% to $1.5 million, driven by interest on cash and securities.

• Cash, cash equivalents, and marketable securities totaled $170.4 million at March 31, 2026.

Outlook and guidance

• Cash and equivalents expected to fund operations for at least the next twelve months.

• Actively enrolling patients in the global IMPROVE-PAH Phase 3 study at approximately 180 sites worldwide.

• Plans to seek additional country approvals in the EU and expand clinical site activations globally.

• Anticipates continued increases in R&D and operating expenses as clinical programs advance.

• No material changes to risk factors; ongoing need for additional capital in the future.